Evidence map›Paper›PMID 20419103›Full record

ArticlePloS one2010

Visualization of transepithelial passage of the immunogenic 33-residue peptide from alpha-2 gliadin in gluten-sensitive macaques.

Kaushiki Mazumdar, Xavier Alvarez, Juan T Borda, Jason Dufour, Edith Martin, Michael T Bethune, Chaitan Khosla, Karol Sestak

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Thin-Plate Superstructures of the Immunogenic 33-mer Gliadin Peptide.Chembiochem : a European journal of chemical biology · 2022
    Article
  6. Dietary Gluten and Neurodegeneration: A Case for Preclinical Studies.International journal of molecular sciences · 2020
    Review
  7. Article
  8. Endocytosis and transcytosis of gliadin peptides.Molecular and cellular pediatrics · 2016
    Article
  9. Review
  10. Article
  11. Article
  12. Non-dietary methods in the treatment of celiac disease.Przeglad gastroenterologiczny · 2015
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Important lessons derived from animal models of celiac disease.International reviews of immunology · 2011
    Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Kaushiki MazumdarDivision of Microbiology, Tulane National Primate Research Center, Covington, Louisiana, United States of America.
Xavier Alvarez
Juan T Borda
Jason Dufour
Edith Martin
Michael T Bethune
Chaitan Khosla
Karol Sestak
Tulane University · USStanford University · US

Funding

ZCM:A NOVEL BROAD-SPECTRUM MICROBICIDE FOR SEXUALLY TRANSMITTED INFECTIONSP51RR000164 · NCRR · TULANE UNIVERSITY OF LOUISIANA · PI VEAZEY, RONALD S. · 1985 to 2011
$100.1M
Role of Transglutaminase 2 in Celiac SprueR01DK063158 · NIDDK · STANFORD UNIVERSITY · PI CHAITAN KHOSLA · 2003 to 2026
$11.2M
Non-Human Primate Model of Gluten-Sensitive EnteropathyR01DK076653 · NIDDK · TULANE UNIVERSITY OF LOUISIANA · PI SESTAK, KAROL · 2008 to 2013
$1.8M
NCRR NIH HHS P51 RR000164NCRR NIH HHS P51RR000164NIDDK NIH HHS R01 DK063158NIDDK NIH HHS R01DK063158NIDDK NIH HHS R01 DK076653NIDDK NIH HHS R01DK076653
6 · The paper itself

Abstract

backgroundBased on clinical, histopathological and serological similarities to human celiac disease (CD), we recently established the rhesus macaque model of gluten sensitivity. In this study, we further characterized this condition based on presence of anti-tissue transglutaminase 2 (TG2) antibodies, increased intestinal permeability and transepithelial transport of a proteolytically resistant, immunotoxic, 33-residue peptide from alpha(2)-gliadin in the distal duodenum of gluten-sensitive macaques. METHODOLOGY/PRINCIPAL

findingsSix rhesus macaques were selected for study from a pool of 500, including two healthy controls and four gluten-sensitive animals with elevated anti-gliadin or anti-TG2 antibodies as well as history of non-infectious chronic diarrhea. Pediatric endoscope-guided pinch biopsies were collected from each animal's distal duodenum following administration of a gluten-containing diet (GD) and again after remission by gluten-free diet (GFD). Control biopsies always showed normal villous architecture, whereas gluten-sensitive animals on GD exhibited histopathology ranging from mild lymphocytic infiltration to villous atrophy, typical of human CD. Immunofluorescent microscopic analysis of biopsies revealed IgG+ and IgA+ plasma-like cells producing antibodies that colocalized with TG2 in gluten-sensitive macaques only. Following instillation in vivo, the Cy-3-labeled 33-residue gluten peptide colocalized with the brush border protein villin in all animals. In a substantially enteropathic macaque with "leaky" duodenum, the peptide penetrated beneath the epithelium into the lamina propria. CONCLUSIONS/SIGNIFICANCE: The rhesus macaque model of gluten sensitivity not only resembles the histopathology of CD but it also may provide a model for studying intestinal permeability in states of epithelial integrity and disrepair.

Indexed as

AnimalsCeliac DiseaseDisease Models, AnimalDuodenumEpitheliumGliadinGlutensHumansMacacaPeptide FragmentsPermeabilityProtein Glutamine gamma Glutamyltransferase 2Protein Transportalpha2-gliadin (56-88)GliadinGlutensPeptide FragmentsProtein Glutamine gamma Glutamyltransferase 2TGM2 protein, human

Identifiers

PMID20419103
PMCPMC2856682
OpenAlexW1966418033

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.